142371-22-0

Upstream product

• 129688-70-6 2-[(4-Bromo-2-fluorophenyl)methyl]-1,2,3,4-tetrahydro-1,3-dioxo-4-isoquinoline-carboxylic Acid Methyl Ester 
• 590-17-0 cyanomethyl bromide 
• 129689-07-2 (2-Carboxyphenyl)propanedioic Acid Dimethyl Ester 
• 137643-17-5 2-(2-Chlorocarbonyl-phenyl)-malonic acid dimethyl ester 
• 112734-22-2 4-bromo-2-fluorobenzylamine 
• 88-65-3 2-bromobenzoic-acid 

Downstream Products

• 129688-94-4 4-(2-amino-2-oxoethyl)-2-<(4-bromo-2-fluorophenyl)methyl>-1,2,3,4-tetrahydro-4-(methoxycarbonyl)-1,3-dioxo-4-isoquinolineacetic acid methyl ester 

Relevant academic research and scientific papers

Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-Bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1

The high concentrations of plasma glucose formed during diabetic hyperglycemia rapidly translate into high levels of glucose in tissues where glucose uptake is independent of insulin. In these tissues that include the lens, retina, nerve, and kidney, this

PROCESS AND INTERMEDIATES FOR THE PREPARATION OF SPIRO(ISOQUINOLINE-4(1H), 3'-PYRROLIDINE)-1,2',3,5'(2H)-TETRONES WHICH ARE USEFUL AS ALDOSE REDUCTASE INHIBITORS

The invention relates to a process for producing spiroisoquinoline pyrrolidines. The compounds have pharmaceutical properties which render them beneficial for the prevention or treatment of diabetes mellitus associated complications.